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Increased lactate dehydrogenase activity is
dispensable in squamous carcinoma cells of origin
A. Flores1,2,7, S. Sandoval-Gonzalez1, R. Takahashi3, A. Krall4, L. Sathe1, L. Wei5, C. Radu 5, J.H. Joly6,7,
N.A. Graham6,7,8, H.R. Christofk 4,5,9,10 & W.E. Lowry 1,2,3,9,10
Although numerous therapeutic strategies have attempted to target aerobic glycolysis to
inhibit tumor progression, these approaches have not resulted in effective clinical outcomes.
Murine squamous cell carcinoma (SCC) can be initiated by hair follicle stem cells (HFSCs).
HFSCs utilize aerobic glycolysis, and the activity of lactate dehydrogenase (Ldh) is essential
for HFSC activation. We sought to determine whether Ldh activity in SCC is critical for
tumorigenesis or simply a marker of the cell type of origin. Genetic abrogation or induction of
Ldh activity in HFSC-mediated tumorigenesis shows no effect on tumorigenesis as measured
by number, time to formation, proliferation, volume, epithelial to mesenchymal transition,
gene expression, or immune response. Ldha-null tumors show dramatically reduced levels of
glycolytic metabolites by metabolomics, and significantly reduced glucose uptake by FDG-
PET live animal imaging. These results suggest that squamous cancer cells of origin do not
require increased glycolytic activity to generate cancers.
Corrected: Author Correction
https://doi.org/10.1038/s41467-018-07857-9 OPEN
1 Department of Molecular Cell and Developmental Biology, UCLA, Los Angeles 90095 CA, USA. 2 Broad Center for Regenerative Medicine, UCLA, Los
Angeles 90095 CA, USA. 3 Division of Dermatology, David Geffen School of Medicine, UCLA, Los Angeles 90095 CA, USA. 4Department of Biological
Chemistry, UCLA, Los Angeles 90095 CA, USA. 5Department of Pharmacology, UCLA, Los Angeles 90095 CA, USA. 6 Department of Engineering, USC,
Los Angeles 90089 CA, USA. 7Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles
90089 CA, USA. 8Norris Comprehensive Cancer Center, University of Southern California, Los Angeles 90089 CA, USA. 9Molecular Biology Institute,
UCLA, Los Angeles 90095 CA, USA. 10 Jonsson Comprehensive Cancer Center, UCLA, Los Angeles 90095 CA, USA. Correspondence and requests for
materials should be addressed to H.R.C. (email: HChristofk@mednet.ucla.edu) or to W.E.L. (email: blowry@ucla.edu)
NATURE COMMUNICATIONS |           (2019) 10:91 | https://doi.org/10.1038/s41467-018-07857-9 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Most tumors are characterized by increased glucoseuptake and lactate production, a phenomenon knownas the Warburg effect or aerobic glycolysis. Elevated
glucose uptake and glycolysis can power the production of
essential metabolites and cell products required for prolifera-
tion1–3. Aerobic glycolysis culminates in the NADH-dependent
reduction of pyruvate to lactate by lactate dehydrogenase
(Ldh)3–6. Although lactate was once considered a waste product
of glycolysis, it has been argued that lactate production may be a
primary purpose of the Warburg effect, as lactate impacts
angiogenesis, immune response, acidification of the micro-
environment, motility of cancer cells, and the regeneration of
NAD+5,7,8. Moreover, inhibition of Ldh activity, which reduces
lactate production, has been shown to impair the growth of tumor
cells in vitro9,10. Regardless, despite decades of research in this
area, it is still not clear whether the increased conversion of
glucose to lactate is necessary for tumor initiation or progression,
or just a by-product of altered metabolism.
In fact, while there is a mountain of data suggesting that lactate
dehydrogenase activity is important for cancer cell growth in
in vitro and ex vivo models11–14, the relevance of lactate pro-
duction to tumor initiation and progression in vivo has not been
well explored. One study that used a model of lung carcinoma
driven by oncogenic Ras coupled with deletion of Ldha showed a
regression of tumors, suggesting a requirement of Ldh activity for
maintenance of tumor cells11. Ldh activity was abrogated in the
entire tissue in that model, however, which left uncertain the role
of glycolytic activity specifically in cancer cells of origin.
Here, we use a model of cutaneous squamous cell carcinoma
(SCC) to model tumor formation and progression from hair
follicle stem cells (HFSCs). HFSCs, which have been shown to be
cancer cells of origin for squamous cell carcinoma15,16, exhibit a
high level of glycolytic activity during homeostatic conditions17.
We therefore sought to determine whether aerobic glycolysis is
required for SCC progression or whether SCC tumors are gly-
colytic simply because they were initiated by glycolytic HFSCs.
Results
Induction of glycolysis in a genetic model of squamous cell
carcinoma. To investigate the relevance of lactate production to
cutaneous squamous cell carcinoma, we used a previously
demonstrated murine model of SCC driven by gain of oncogenic
Ras coupled with loss of p53 activity in HFSCs15. Transgene
expression was targeted to HFSCs using transgenic alleles such as
K15CrePR or Lgr5CreER18,19 with induction of Cre recombina-
tion through administration of mifepristone or tamoxifen.
We first investigated whether lactate synthesis correlates with
tumor grade. We typically characterize squamous tumors in the
following categories: hyperplasia, low grade papilloma/keratoa-
canthoma stage, medium-grade squamous carcinoma, and high-
grade undifferentiated squamous carcinoma (Fig. 1a). While Ldh
activity, as measured by in situ activity, was elevated relative to
normal skin in all examined tumor grades, the activity of Ldh
appeared to peak at the papilloma/keratoacanthoma stage, and
decreased somewhat in high-grade tumors (Fig. 1b). These results
were confirmed by a more quantitative analysis of Ldh activity in
lysate from isolated tumor tissues of various stages (Fig. 1b).
For a more comprehensive metabolic analysis, we also
performed liquid chromatography mass spectrometry (LCMS)-
based metabolomics on tumor tissue from various stages of
tumorigenesis. This analysis showed that as the skin became filled
with tumorigenic cells, the steady-state levels of some glycolytic
metabolites increased, particularly in the medium grade stage
(Fig. 1c). We also performed glucose tracing experiments in which
animals with tumors at various stages were intraperitoneally
injected with [U-13C6] glucose 15 min prior to skin and tumor
harvesting and metabolite extraction in order to follow the
conversion of glucose to various metabolites. More 13C-labeled
lactate in the M3 isotopomer form was detected in the medium-
grade papillomas than in the low-grade or high-grade tumors
(Fig. 1d). These analyses are consistent with an increased
conversion of glucose to lactate as SCC initiated and progressed,
with a peak of lactate labeling from glucose in the medium grade,
and a drop off somewhat in high-grade tumors.
Finally, we measured gene expression changes in HFSCs as
they proceed through various stages of tumorigenesis. Expression
of Ldha in HFSC-derived tumors was not elevated relative to
normal HFSCs (Supplementary Figure 1), which we previously
showed to have high expression of Ldha relative to other types of
cells in the skin17. In contrast, expression of other glycolytic
enzymes, such as Pgm, HK, Pgk, Pkm2, and Eno, were further
increased during tumorigenesis. Furthermore, transcriptome data
demonstrated that transporters for lactate, pyruvate, glucose, and
glutamine were all upregulated. These data suggested that despite
the relatively high glycolytic rate of HFSCs under homeostatic
conditions17, glycolysis may be further induced upon
tumorigenesis.
Genetic abrogation of Ldh activity during initiation of SCC. To
determine whether induction of lactate production in HFSCs is
required for squamous cell carcinoma initiation, we induced
tumorigenesis in HFSCs in the context of Ldha deletion. For this
purpose, we coupled conditional deletion of p53 and activation of
constitutively active Kras (LSL-KrasG12D) with inducible dele-
tion of floxed-Ldha with either K15CrePR- or Lgr5CreER-medi-
ated recombination, which we previously showed effectively
abrogates lactate production in HFSCs15,17,20.
Contrary to numerous observations linking glycolysis and
lactate production to tumorigenesis, KrasG12D-p53fl/fl-mediated
SCC tumor formation from HFSCs was not affected by loss of
Ldha (Fig. 2a). Quantification of tumorigenesis showed that
neither the timing, volume, nor number of tumors formed was
affected by loss of Ldha (Fig. 2b). These results were confirmed by
induction of oncogenesis by a distinct HFSC-specific Cre
(Lgr5CreER) (Fig. 2b) and through DMBA/TPA administration,
a classical SCC paradigm (Fig. 2b)21. DMBA/TPA tumors were
stratified as null or mosaic for Ldha expression.
We next attempted to more carefully characterize tumors
generated from wild-type or Ldha-null HFSCs. Ldha wild-type
and null tumors were not distinguishable pathologically;
both sets of tumors showed hallmarks of spindle cell proliferation,
papillomatous papulae, infiltration, etc (Supplementary Figure 2a).
Because it has been suggested that tumor-generated lactate can
suppress immune activity, we additionally explored the possibility
that tumors could elicit distinct immune responses depending on
their expression of Ldha (Supplementary Figure 2b and c).
However, we were unable to detect a distinct pattern of immune
response in the absence of Ldh activity. We also compared
proliferation, epithelial to mesenchymal transition (EMT), mar-
kers of HFSC fate, and total gene expression (Supplementary
Figure 3a). Staining for Ki67 to measure proliferation did not
identify any significant difference between tumors that express or
lack Ldha. Staining for markers of EMT showed that all tumors
upregulated mesenchymal markers (such as fibronectin and
tenascin C) and downregulated epithelial markers (such as keratin
14), regardless of Ldha status. HFSCs are known to express
markers such as CD34 and Sox9 (as well as secrete Tnc)22–24.
Immunostaining for these HFSC markers showed that tumors
generated from HFSCs do indeed continue to express
Sox9 and CD34, and that this is not affected by loss of Ldha.
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Hypoxia is a common phenotype in a majority of malignant
tumors and has been shown to alter tumor metabolism,
vascularization, and epithelial-to-mesenchymal transition. There
were no observed differences in hypoxia levels in tumors due to
loss of Ldha (Supplementary Figure 3b). Finally, to identify any
molecular changes in tumors due to loss of Ldha, we performed
RNA-seq on six tumors that express Ldha versus six that were
deleted for Ldha. Following normalization, stringent analysis
failed to detect significant gene expression changes associated
with loss of Ldha. In particular, we examined the same genes
described to be induced during SCC generation from HFSCs
(Supplementary Figure 1), and found that none of these genes or
pathways were distinctly different in tumors formed in the
absence of Ldh activity (Supplementary Figure 3c). Collectively,
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these data suggest that Ldha is not essential for SCC tumor
formation.
Measuring metabolism in Ldha-null tumors. One explanation
for the lack of effect of loss of Ldha on tumor formation could be
that another Ldh isoform (Ldhb, Ldhc, or Ldhd) was able to
compensate for the loss. To determine whether Ldha-null tumors
had indeed lost Ldh enzymatic activity, we assayed activity with
several independent methods. First, we used an in situ activity
assay to identify tumors or areas within tumors that show Ldh
activity. All tumors genotypically positive for Ldha showed robust
Ldh activity (Fig. 3a). Amongst the Ldha-null tumors, most had
completely lost Ldh activity in this assay, while some showed
mosaic activity, presumably due to the inducible method of Cre
recombination employed. There was no difference in appearance
between the tumors that had full activity, lacked activity, or were
mosaic for Ldh activity (Fig. 3a). Second, we examined Ldh
activity in cell lysate from isolated tumors, which confirmed the
absence of Ldh activity in Ldha-null tumors (Fig. 3b, c). Finally,
we used LCMS-based metabolomics to measure the relative level
of lactate in all the tumors analyzed. This analysis showed that
lactate and most of the other glycolytic metabolites were dra-
matically lower in Ldha-null tumors (Fig. 3d). Relative levels of
TCA cycle metabolite pools and glucose-labeled TCA metabolites
were also analyzed in Ldha wild-type versus Ldha-null tumors
and not many significant changes were observed (Supplementary
Figure 4). In addition, the NAD+/NADH ratio was reduced in
Ldha-null tumors, consistent with decreased oxidation of NADH
to NAD+ (Fig. 3e). Further, animals were injected with [U-13C6]
glucose prior to tumor harvesting to measure glucose utilization.
Glucose labeling of lactate as well as all other examined glycolytic
metabolites was dramatically reduced in Ldha-null tumors
(Fig. 3f). Together, these data strongly suggest that the tumors
formed in genotypically Ldha-null mice in fact lost Ldh activity
without compensation from any other Ldh isoform (b, c, d).
To determine whether the depletion of glycolytic intermediates
in Ldha-null tumors (Fig. 3d) was due to reduced glucose
consumption, we performed FDG-PET on our mice with Ldha
wild-type and null skin tumors. FDG is a glucose analogue that
can be non-invasively imaged by positron emission
tomography (PET)25,26. Tumors are known to be highly
glycolytic and take up significantly more FDG than normal
tissue, and this was observed in all tumors expressing Ldha
(Fig. 4a). On the other hand, tumors null for Ldha, showed
significantly less FDG uptake relative to Ldha wild-type tumors.
This was the case in both tumors induced by KrasG12D/loss of
p53, as well as tumors generated by DMBA/TPA (Fig. 4b). These
data indicate that tumors deficient in Ldh activity abrogate their
glucose uptake.
Abgrogation of Ldh activity during tumor progression. The
fact that loss of Ldh activity did not affect tumor initiation raised
the possibility that lactate production is important for tumor
progression as opposed to tumor initiation. To test this hypoth-
esis, we administered DMBA/TPA for several weeks until the first
signs of tumorigenesis27–29 then deleted Ldha by Cre activation
with Mifepristone in transgenic animals. The experiment was
allowed to continue for several more weeks, and the results were
quantified. We were unable to detect an effect of loss of Ldh
activity even in existing tumors (Fig. 5a). Deletion of Ldha in the
midst of tumor formation did not affect the timing or degree of
tumorigenesis (Fig. 5b). Ldha deletion was confirmed by in situ
staining for Ldh (Fig. 5c), Ldh activity in tumor lysate (Fig. 5d),
and western blotting (Fig. 5e).
Stimulation of Ldh activity during tumorigenesis. To comple-
ment the Ldha deletion experiments, we examined whether
enhancing Ldh activity influences SCC tumorigenesis. For this
purpose, we genetically induced lactate production through the
deletion of mitochondrial pyruvate carrier (Mpc1), an obligate
component of the mitochondrial pyruvate carrier. We and others
previously showed that inhibiting the ability of pyruvate to enter
the mitochondria leads to increased Ldh activity17,30, and deleting
Mpc1 with K15CrePR or Lgr5CreER-mediated recombination
effectively increases lactate production specifically in HFSCs17.
Here, we used a floxed Mpc1 allele in conjunction with DMBA/
TPA to induce tumorigenesis in cells with enhanced Ldh activity.
Deletion of Mpc1 in these tumors led to a two-fold increase in
Ldh activity, (Fig. 6c, d). However, as with Ldh deletion, Ldh
activation failed to affect the timing or degree of tumorigenesis
(Fig. 6a, b). We also considered the possibility that the combi-
nation of KrasG12D and p53 loss may be too potent for Mpc1
loss to further increase tumorigenesis. To address this possibility,
animals were created that coupled Mpc1 loss to the single
oncogenic hit of KrasG12D (Fig. 6e), which, when induced in
HFSCs, only leads to benign hyperplasia in the follicle15. How-
ever, although Ldh activity (Fig. 6f) and lactate labeling by glucose
carbons (Fig. 6g) were elevated by Mpc1 loss, the rate or degree of
tumorigenesis was unaltered in this model (Fig. 6a, b).
Examination of metabolite flux in the absence of Ldh activity.
These data suggest that aerobic glycolysis is not necessary for
tumor initiation or progression. It is thought that the increased
glucose uptake and lactate production characterized by the
Warburg effect increases the availability of metabolic inter-
mediates needed for macromolecule biosynthesis. We therefore
examined whether Ldha-null tumors use alternative carbon
sources to fuel biosynthetic processes. Recent studies have shown
that lactate in the blood can readily be used as a carbon source to
Fig. 1 Correlation of Ldh activity and tumorigenesis of SCC. Haematoxylin and eosin staining showing histology of squamous tumors of various stages: low-
grade papilloma/keratoacanthoma stage, medium-grade squamous carcinoma, and high-grade undifferentiated squamous carcinoma. Scale bars, 200 µm.
b In situ Ldh activity assay highlights maximal potential Ldh activity in murine skin during KrasG12D/p53mediated SCC formation from HFSCs. Purple stain
indicates relative Ldh activity in the skin of control (top left; +mifepristone/-oncogenic stimulation) versus hyperplasia stage (top right; +mifepristone/
+oncogenic stimulation), papilloma stage (lower left), and high-grade SCC (lower right) Scale bars, 200 µm. b (right panel) Ldh activity in lysate from
tissue of the indicated stage of tumorigenesis. Each bar represents the average activity for each tumor type where n= 6 tumors per stage from 24 animals.
Shown as mean ± SEM. Paired t test was performed, p < 0.05 shown for each tumor type versus control tissue. c Metabolites were extracted and analyzed
by LCMS from four tumors (1–4) from each stage of tumorigenesis (12 animals total). Glucose (Glc) and glycolytic intermediate levels are shown as
relative values to the low grade tumor group. d following intraperitoneal injection of animals with [U-13C6]glucose, tumors at various stages were isolated
and profiled by metabolomics. Labeled metabolites were extracted and analyzed by LC–MS from four tumors (1–4) from each stage of tumorigenesis
(12 animals total). Heatmap depicts percentage of indicated isotopomers of glucose and glycolytic intermediates labeled from the U-13C-glucose tracer.
For (c), error bars denote SD (n= 4 individual tumors). For (c, d), *P<0.05; **P<0.01; ***P<0.001 by Student’s t test
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Fig. 2 Loss of Ldha does not affect tumor initiation, progression or pathology. a Pathology of KrasG12D/p53 induced tumors from HFSCs with and without
Ldha deletion appear indistinguishable across tumorigenesis. Scale bars, 200 µm. b Quantification of time to tumor formation (left), the number of tumors
formed, or the tumor volume showed no significant difference between Ldha expressing vs. Ldha deleted tumors. Also shown is results from animals where
KrasG12D/p53 was generated under the control of the Lgr5CreER, or in independent experiments where chemical carcinogenesis (DMBA/TPA) was carried
out. Each bar represents the average across indicated values for n. Shown as mean ± SEM. Paired t test was performed, P < 0.05 shown for each genotype
versus wild-type control
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Fig. 3 Metabolic effects of loss of Ldha during tumorigenesis. a In situ measurement of maximal Ldh activity in tumors with and without Ldha deletion
shows a dramatic loss of activity in most tumors from the Ldha deletion mice (middle row). Activity is indicated by purple color; pink is a nuclear
counterstain. In addition, some tumors formed in deletion mice show mosaicism for Ldh activity, presumably due to mosaic deletion of Ldha mediated by
CrePR induced recombination. Scale bars, 200 µm. b Ldh activity in lysate derived from tumors of the indicated stages. Those samples with * indicated
tumors that were deemed to be mosaic for Ldha deletion by the in situ assay. Each bar represents the average signal for each tumor type where n= 6 mice
per tumor stage and genotype from 42 animals. Shown as mean ± SEM. Paired t test was performed, P < 0.05 shown for each tumor type versus control
skin. cWestern blotting for Ldha protein indicated the effectiveness of the genetic deletion. d Heatmap depicts relative levels of glycolytic intermediates as
measured by LCMS in tumors from animals with and without Ldha expression. Each column represents metabolite measurements from an individual
animal, and 20 animals were used, 10 of each genotype. e NAD+/NADH ratio in Ldha wild-type (+/+) vs. Ldha null (fl/fl) tumors. Each bar represents the
relative NAD+/NADH ratio where n= 10 mice per genotype. Shown as mean ± SEM. Paired t test was performed, P < 0.05 shown for knockout versus
wild-type tumors. f Heatmap depicts percentage of glycolytic intermediate isotopomers in tumors with indicated genotypes from animals IP injected with
[U-13C6] glucose 15 min prior to tumor harvesting. For (d, f), ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; NS, P > 0.05. Student’s paired t test
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power the TCA cycle. Although lactate is thought to be meta-
bolized primarily through Ldh-dependent pyruvate generation,
we considered whether Ldha-null tumors could oxidize imported
lactate via alternative dehydrogenases to power the TCA cycle. To
test this possibility, we injected mice with [U-13C3] lactate and
performed metabolomics on both wild-type and Ldha-null
tumors. However, there was no significant difference in the
amount of lactate uptake in the absence of Ldh activity (Fig. 7a).
While metabolomic analyses showed lactate lactate-labeling of
TCA cycle intermediates including citrate, alpha-ketoglutarate,
succinate, fumarate, and malate, though there was no significant
difference in labeling between wild-type or Ldha-null tumors
(Supplementary Figure 5).
Finally, we examined whether Ldha-null tumor cells increase
glutamine utilization from the environment as a carbon source.
Glutamine is imported into the cell through the Slc1a5
transporter and can fuel the TCA cycle through glutaminase-
mediated conversion to glutamate. mRNA levels of both Slc1a5
and glutaminase were upregulated in HFSC-induced SCC (Fig S1
and Fig. 7b), raising the possibility that glutamine metabolism
may be increased in SCC formation35. To determine whether loss
of Ldh activity promotes glutamine metabolism, we measured
glutaminase activity in tumor lysate. Ldha-null tumors exhibited
elevated glutaminase activity relative to wild-type tumors (n= 6)
(Fig. 7c). In addition, tumor glutamine metabolism was assessed
through tumor glutamine tracing with injected [U-13C5]
glutamine. Metabolomics analysis of glutamine-labeled tumors
indicated that Ldha-null tumors did indeed take up more
glutamine than wild-type tumors (Fig. 7d). Moreover, Ldha-null
tumors showed increased glutamine labeling of several TCA cycle
metabolites via oxidative glutamine metabolism (Fig. 7e) and
reductive glutamine metabolism (Fig. 7f), consistent with
increased use of glutamine as a biosynthetic carbon source in
the absence of Ldh activity.
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Discussion
Based on decades of research showing that nearly all tumors
display increased lactate production, our null hypothesis was that
deletion of Ldha would block tumor formation from HFSCs. In
addition, Ldha deletion in a model of lung tumor formation
caused tumors to regress11. Despite the fact that this lung model
also used KrasG12D and floxed p53, the outcome was different
than what was observed here in a model of cutaneous SCC. The
difference could be due to performing the experiments in distinct
tissues, but the lung study also used deletion of Ldha in the entire
tissue, and deleted Ldha only after tumors were established11.
Altered metabolism of cells in the lung tumor environment due to
global Ldha deletion may have resulted in a different outcome.
Alternatively, the lung and the epidermis are distinct tumor
environments with distinct nutrient availabilities. The tumor
environment may enable cutaneous SCC to adapt to nutrients
generated by other cells of the epidermis, whereas alternative
nutrient limitation may necessitate lung cancer dependence on
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glucose metabolism. In fact, a recent study showed that only
certain types of lung tumors are sensitive to inhibition of glyco-
lysis and certain lung tumors require inhibition of both glycolysis
and glutamine pathways to block tumorigenesis5, suggesting that
different types of tumors have different metabolic requirements.
In addition, Ldh expression appears to be distinct between the
lung and skin. In the lung, it appeared from the Seth et al. study
that Ldhb is expressed significantly higher than Ldha, while the
reverse is true in the skin11,17 (Fig. 1). It is interesting that after
deletion of Ldha, cutaneous SCC still formed from HFSCs
without compensation by Ldhb. Furthermore, deletion of Ldha in
SCC appeared to strongly abrogate total Ldh activity, demon-
strating that Ldha is the dominant isoform in the skin model.
Previous studies have shown LDHA expression predicts worse
survival in clear cell renal cell carcinoma21, cholangiocarci-
noma30, and breast cancer31. Taking advantage of multiple
databases for human cancers and a novel aggregator called
CANCERTOOL32, it is clear that LDHA expression is increased
in a variety of human cancers (Supplementary Figure 6a). How-
ever, despite this increase in expression (and presumably activity),
LDHA expression levels do not universally correlate with patient
outcomes (Supplementary Figure 6b). The fact that LDHA
expression does not always predict survival even in human
tumors in which it is upregulated is consistent with our findings
that Ldha expression is elevated in SCC but not required for SCC
tumor growth in the mouse skin and may underlie fundamental
differences in metabolic dependencies or enhanced metabolic
flexibility of squamous cell carcinomas relative to other tumor
types.
In the current study, we found that deletion of Ldha neither
before nor after tumor formation had an effect on the outcome,
demonstrating that Ldh activity in cancer cells of origin is not
required for tumor initiation or progression in SCC. These results
are consistent with the notion that high Ldh activity in tumors
could be due to the fact that at least some cancer cells of origin are
high in Ldh activity. Indeed, if the Warburg nature of SCC is
more a reflection of expansion of phenotype of the cell from
which it arose (Supplementary Figure 3), this could explain why
loss of Ldh activity had no significant effect on tumorigenesis. It is
also possible that the increased Ldh activity observed in tumors
could be oncogene or even tissue dependent, and additional
studies are necessary to determine to what extent cell of origin,
tumor suppressors, oncogenes, and tumor microenvironment
contribute to this common phenotype.
The longer-term question is why do tumors produce so much
lactate if it is not required for their initiation or maintenance?
Lactate was previously considered simply a waste product of
glycolysis, which could explain why loss of lactate production in
SCC does not appear to have a consequence in our model. On the
other hand, recent studies have indicated that lactate is potentially
an important molecule to suppress the immune response to
tumor formation, affect angiogenesis, acidify the microenviron-
ment, and increase the motility of cancer cells. Additionally,
the conversion of pyruvate to lactate by Ldh enzyme produces
NAD+, and the NADH/NAD+ ratio is thought to be important
in numerous oxidoreductase-based metabolic reactions (reviewed
in refs. 27–29). As a result, some have argued that the entire
purpose of the Warburg effect is to produce lactate for the sake of
driving these events that are known to be important for tumor
formation27.
In light of data showing that lactate can act at a distance, it is
also important to consider where lactate is produced. Two studies
in mouse and human demonstrated that in fact lactate is found at
very high concentration in the blood and can even be used to
power the TCA cycle in both normal tissue and tumors 27,33. It is
known that tissues such as muscle are highly glycolytic and
produce lactate that ends up in the circulation35–37. It is thought
that lactate produced in the muscle then can act at a distance in a
process known as the lactate shuttle, to participate in gluconeo-
genesis and even act as an agonist with the hormone receptor
GRP81, such that lactate potentially acts as a “lactormone” 27. It is
tempting to speculate that the lactate produced by tumors is
meant to act as a signal to alert the entire body to the presence of
a metabolic disruption, and therefore loss of lactate production in
SCCs would not affect the progression of the tumor in our
murine model, but instead how the entire system may respond to
tumor formation.
Our original hypothesis based on the expression pattern and
activity of Ldha during SCC progression was that Ldh inhibition
would abrogate tumor growth. However, the data demonstrate
instead that while in vivo deletion of Ldha did affect the meta-
bolism of the tumors formed, this did not affect cancer cell
proliferation, survival, pathology, immune response etc. Perhaps
in vitro data showing that Ldh inhibition can block tumor growth
are incomplete because tumor cells in vivo can take up lactate
from the blood to make up for the loss of Ldh activity in the
treated cells. Metabolomics data from SCCs without Ldh activity
showed that whether tumors are making lactate or taking it up
from the circulation, not only is the pool of lactate low in SCCs,
but also lactate production is low. Furthermore, the lack of Ldh
activity also corresponded to a negative feedback whereby all the
glycolytic metabolites were decreased, suggesting that increased
glucose utilization in general is not required for tumor initiation
or progression in SCC. These results could provide a simple
explanation for why several efforts to exploit Ldh inhibition to
treat cancer have not progressed beyond early stage clinical trials.
Recent studies have suggested that tumors are metabolically
flexible, which could explain why loss of Ldh activity did not
affect initiation or progression of SCCs. In this scenario, tumors
lacking the ability to use glucose to produce lactate simply take up
other metabolites, such as glutamine to generate products
necessary for increased biomass during proliferation. In response
to loss of glucose catabolism, oxidative and reductive glutamine
metabolism could be simultaneously increased across a tumor
mass as a result of heterogeneity of oxygen tension across the
tumor. Hypoxia is known to promote tumor reductive glutamine
metabolism38, so it is conceivable that hypoxic regions could
exhibit increased reductive glutamine metabolism whereas better
perfused regions could exhibit enhance oxidation glutamine
metabolism.
We used glutamine labeling to trace uptake and metabolism
and did indeed find that Ldha-null tumors took up and used
more glutamine to power their metabolism. Although there was
no difference in [U-13C3] lactate labeling of TCA cycle meta-
bolites, Ldha-null tumors increased uptake and TCA cycle
metabolism of [U-13C5] glutamine, suggesting the use of gluta-
mine as a carbon source to compensate for reduced glycolysis/
glucose metabolism. These results suggest that Ldha-null tumors
may be sensitized to glutaminase inhibition35. An outstanding
question from this work is to understand whether this increased
glutamine uptake and utilization compensates for loss of glucose
metabolism in the absence of Ldh activity. It is possible that dual
inhibition of both Ldh activity and glutamine uptake or gluta-
minase could potentially starve tumors by circumventing their
metabolic flexibility, and this will be the focus of effort going
forward.
Methods
Animal experiments. All animal experiments and related procedures were per-
formed in accordance with protocols approved by the Institutional Animal Care
and Use Committee (IACUC) at UCLA in facilities run by the UCLA Department
of Laboratory Animal Medicine (DLAM). Animal strains came from Jackson Labs
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(K15-CrePR, Lgr5-CreER), the National Cancer Institute Mouse Models of Human
Cancers Consortium repository (LSL-KrasG12D and p53fl/fl), the Rutter (Mpcfl/fl)
and Seth laboratories (Ldhafl/fl) and were maintained under conditions set forth by
IACUC and UCLA Animal Resource Committee. For tumor initiation experi-
ments, K15-CrePR animals were shaved and treated by injection of mifepristone,
and Lgr5-CreER animals were shaved and treated with tamoxifen (200 μl of 10 mg
ml−1 dissolved in filtered sunflower seed oil daily for 3 days) during telogen
(7–8 weeks postnatal), and monitored for hair and tumor growth following
shaving. Tumors generated in K15-CrePR animals were harvested for analysis
8–9 weeks post mifepristone induction, and tumors generated in Lgr5-CreER
animals were harvested 14–16 weeks post tamoxifen induction. For tumor pro-
gression experiments, tumors were generated in K15-CrePR and Lgr5-CreER
animals floxed for either Ldha or Mpc1 by cutaneous two-stage chemical carci-
nogenesis39. Briefly, transgenic animals (7–8 weeks postnatal) were shaved and
treated once on the shaved dorsal skin with 200 nmol of DMBA dissolved in
acetone. One week later, 5 nmol TPA dissolved in 100% ethanol was applied to the
dorsal skin. In total, 5 nmol TPA treatment continued twice a week for the duration
of the experiment. At the first visible sign of tumor formation, K15-CrePR and
Lgr5-CreER mice were treated with mifepristone and tamoxifen, respectively to
delete Ldha or Mpc1. Mifepristone or tamoxifen were administered by intraper-
itoneal injection (200 μl of 10 mgml−1 dissolved in filtered sunflower seed oil daily
for 3 days). Tumors were harvested for analysis 19–20 weeks post initial DMBA
treatment. Both male and female animals were used in this study in approximately
equal numbers with no apparent difference in phenotype between genders. All
animals shown were maintained on a mixed C57BL6/FVB background. No sta-
tistical measure was used to determine the sample size beforehand. The results
described include data from all treated animals. The investigators were not blinded
to allocation during the experimental data collection, nor were the experiments
randomized. The results shown are representative images from at least three
independently treated animals per genotype as denoted in each experimental
legend, and genotyping was performed both before and after animal treatment for
confirmation.
Histology and immunostaining. Tumors were isolated from animals of indicated
genotypes and embedded fresh in OCT compound for frozen tissue preparations,
or fixed overnight in 4% formalin and embedded in paraffin. Formalin-fixed
paraffin-embedded (FFPE) tumor sections were cut at 5 μm and fresh frozen
tumors in OCT compound were cut at 10 μm for hematoxylin and eosin staining,
and immunostaining. Immunohistochemistry on FFPE tissue sections was per-
formed (White et al.15). Briefly, paraffin-embedded tumor sections were de-par-
affinized, rehydrated, and blocked in staining buffer containing appropriate control
IgG (goat, rabbit etc.). Antigen retrieval was performed on formalin-fixed paraffin-
embedded tumor sections with citrate or Tris-EDTA buffers for 30 min at 95 °C
with the following antibodies: Ki-67 (Abcam, ab16667, 1:50), p-S6 (Cell Signaling,
CST2215, 1:50), Sox9 (Abcam, ab185230, 1:1,000), CD34 (Abcam ab81289,
1:1000), K14 (Covance, PRB-155P, 1:800), Fibronectin (Abcam, ab2413, 1:250),
Tenascin C (Abcam ab108930, 1:500). The DAKO EnVision + HRP Peroxidase
System (Dako K400911-2) and Dako AEC Substrate Chromogen (Dako K346430-
2) was used for detection. Images were collected on an Olympus BX43 Upright
Microscope. For hypoxia staining, HypoxyprobeTM-1 solution (pimonidazole HCl)
(Hypoxyprobe, HP3-100Kit) was administered to mice by intraperitoneal injection
at a dosage of 60 mg/kg 45 min before harvest of skin. Tissue was embedded,
sectioned, and stained as described above using affinity purified anti-pimonidazole
rabbit antisera containing 0.09% sodium azide and 1% BSA (PAb2627AP, 1:100).
Western blotting. Fresh tumor samples were homogenized with a tissue micro-
grinder followed by mechanical dissociation with a syringe and cell lysis in RIPA
buffer (Pierce) with Halt protease and phosphatase inhibitors (Thermo-Fisher) on
ice. After removing insoluble material by centrifugation at 8000g at 4 °C for 5 min,
total protein concentration was determined using the BCA assay kit (Pierce) per
manufacturer’s protocol with a microplate reader. Twenty micrograms of protein
per tumor sample was diluted in SDS-PAGE gel electrophoresis sample buffer (Bio-
Rad) and boiled at 95 °C for 5 min. Denatured proteins were resolved on SDS-
PAGE gels (NuPAGE Novex Gels, Thermo-Fisher) and transferred onto PVDF
membranes (Bio-Rad). Blocking was done with 5% milk in PBST, and then
membranes were incubated with primary antibodies; β-actin (Abcam, ab8227;
1:1000), Ldha (Cell Signaling, CST2012; 1:1000), Mpc1 (Sigma HPA045119; 1:500)
overnight at 4 °C. After washing, membranes were incubated with peroxidase-
conjugated secondary antibodies for 1 h at room temperature. Signals were detected
with Pierce ECL Western Blotting Substrate following washes.
Ldh activity assay in tumor lysate. Ldh activity was determined in tumor cell
lysates by measuring the formation of soluble XTT formazan in direct relation to
production of NADH over time at 475 nm at 37 °C using a SynergyMX plate reader
(Biotek Instruments). Fresh tumor samples were homogenized with a tissue
microgrinder followed by mechanical dissociation with a syringe and cell lysis in
RIPA buffer (Pierce) with Halt protease and phosphatase inhibitors (Thermo-
Fisher) on ice. After removing insoluble material by centrifugation at 8000g at 4 °C
for 5 min, total protein concentration was determined using the BCA assay kit
(Pierce) per manufacturer’s protocol with a microplate reader. Ten micrograms of
protein was used per well for each tumor. Samples were run in triplicates. The
staining solution contained 50 mM Tris buffer pH 7.4, 150 μM XTT (Sigma),
750 μM NAD (Sigma), 80 μM phenazine methosulfate (Sigma), and 10 mM of
substrate lactate (Sigma). Ldh activity was determined in cell lysates by measuring
the change in absorbance of their common substrate or product, NADH, over time
at 340 nm at 25 °C using a Synergy-MX plate reader (Biotek Instruments).
In situ Ldh assay. Ten-micron cryostat sections of fresh frozen tumors were briefly
fixed (4% formalin for 5 min), washed with PBS pH 7.4 for 10 min, and then
incubated with the appropriate solution for Ldh activity. Ldh staining solution
contained 50 mM Tris pH 7.4, 750 μM NAD (Sigma), 80 μM phenazine metho-
sulfate (Sigma), 600 μM nitrotetrazolium blue chloride (Sigma), 10 mM MgCl2
(Sigma), and 10 mM of the substrate lactate (Sigma). Slides were incubated with
staining solution at 37 °C until they reached the desired intensity, then counter-
stained using Nuclear Fast Red (Vector) or Braziliant! (Anatech) and mounted
using VectaMount (Vector). Control reactions were performed by using staining
solution that lacked the substrate mixture or NAD.
Glutaminase activity assay. Glutaminase activity was determined in tumor cell
lysates by measuring the formation of soluble XTT formazan in direct relation to
production of NADH over time at 475 nm at 37 °C using a SynergyMX plate reader
(Biotek Instruments). The glutaminase assay used was modified from the in situ
assay described in Montero et al. and Botman et al. 40,41. Fresh tumor samples were
homogenized with a tissue microgrinder followed by mechanical dissociation with
a syringe and cell lysis in RIPA buffer (Pierce) with Halt protease and phosphatase
inhibitors (Thermo-Fisher) on ice. After removing insoluble material by cen-
trifugation at 8000g at 4 °C for 5 min, total protein concentration was determined
using the BCA assay kit (Pierce) per manufacturer’s protocol with a microplate
reader. Ten micrograms of protein was used per well for each tumor. Samples were
run in triplicates. In control reactions either glutamine or phosphate was omitted,
or the protein denatured. The staining solution contained 200 mM Tris-HCl buffer
(pH 8.0); 200 mM KH2PO4; 40 mM glutamine; 0.1 mM EDTA; 3.4 mM NAD+
(Sigma); 0.5 mM ADP (Sigma); 0.3 mM XTT (Sigma); 0.49 mM phenazine meth-
osulfate (Sigma); and 100 units of glutamate dehydrogenase used as an auxiliary
enzyme (GIDH) (Sigma). Glutaminase activity was determined in cell lysates by
measuring the change in absorbance of their common substrate or product,
NADH, over time at 340 nm at 25 °C using a Synergy-MX plate reader (Biotek
Instruments).
LCMS-based metabolomics analysis. The experiments were performed as pre-
viously described17. To extract intracellular metabolites from tumor cells, fresh
tumor samples of approximately the same volume (0.15 cm3) were briefly rinsed
with cold 150 mM ammonium acetate (pH 7.3), followed by addition of 1 ml cold
80% methanol/20% water and homogenization on dry ice with a tissue micro-
grinder and mechanical dissociation through a syringe. Cell suspensions were
transferred into Eppendorf tubes, and 10 nmol D/L-norvaline was added as a
loading control for the instrument. After rigorously mixing, the suspension was
pelleted by centrifugation (18,000g, 4 °C for 5 min). The supernatant was trans-
ferred into a glass vial, metabolites dried down under vacuum, and resuspended in
70% acetonitrile/30% water. Cell pellets were resuspended in RIPA buffer (Pierce)
with Halt protease and phosphatase inhibitors (Thermo-Fisher) on ice. After
removing insoluble material by centrifugation at 8000g at 4 °C for 5 min, total
protein concentration was determined using the BCA assay kit (Pierce) per
manufacturer’s protocol with a microplate reader. For the mass spectrometry-based
analysis of the sample, 5 μl was injected onto a Luna NH2 (150 mm × 2mm,
Phenomenex) column. The samples were analyzed with an UltiMate 3000RSLC
(Thermo Scientific) coupled to a Q Exactive mass spectrometer (Thermo Scien-
tific). The Q Exactive was run with polarity switching (+3.50 kV/−3.50 kV) in full
scan mode with an m/z range of 65–975. Separation was achieved using: (A) 5 mM
NH4AcO (pH 9.9) and (B) ACN. The gradient started with 15% (A) going to 90%
(A) over 18 min, followed by an isocratic step for 9 min and reversal to the initial
15% (A) for 7 min. Metabolites were identified with TraceFinder 3.3 using accurate
mass measurements (≤3 ppm) and retention times. Metabolite data were normal-
ized to tumor protein concentration and norvaline as an internal standard for
metabolite extraction and are available at figshare.com (https://doi.org/10.6084/m9.
figshare.c.3801271). For experiments with labeled isotope tracing ([U-13C6] glu-
cose, [U-13C5] glutamine, and [U-13C3] lactate; Cambridge Isotope Laboratories
Inc. CLM-1396-5, CLM-1822-H-0.1, CLM-1579-0.5), the labeled isotope was
delivered by intraperitoneal injection (2 g/kg in PBS) 15 min prior to euthanasia.
Tumor samples were then harvested and prepared as described above.
RNaseq and bioinformatics. To compare gene expression profiles from tumors
with and without Ldha, total RNA was isolated from fresh tumor samples. Fresh
tumor samples were placed in Trizol LS reagent and homogenized by vortexing,
microgrinding, and mechanical dissociation through a syringe. Total RNA isolation
was subsequently performed using an RNeasy Mini Kit (Qiagen) following the
manufacturer’s protocol with chloroform, isopropanol, and ethanol washes.
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Total RNA sample QC: All samples need to pass through the following four
steps before library construction: (1) Nanodrop: tests RNA purity (OD260/
OD280), (2) Agarose Gel Electrophoresis, (3) Agilent 2100 to check RNA integrity.
Library construction: After the QC procedures, mRNA from tumor samples was
enriched using oligo(dT) beads. The mRNA was then fragmented randomly in
fragmentation buffer, followed by cDNA synthesis using random hexamers and
reverse transcriptase. After first-strand synthesis, a custom second-strand synthesis
buffer (Illumina) was added with dNTPs, RNase H, and Escherichia coli polymerase
I to generate the second strand by nick-translation. The final cDNA library was
ready after a round of purification, terminal repair, A-tailing, ligation of sequencing
adapters, size selection, and PCR enrichment.
Library QC: Library concentration was first quantified using a Qubit 2.0
fluorometer (Life Technologies), and then diluted to 1 ng/µl before checking insert
size on an Agilent 2100 and quantifying to greater accuracy by quantitative PCR
(Q-PCR) (library activity >2 nM).
Sequencing: Libraries were sequenced on HiSeq2500 (Illumina).
Data filtering: Raw reads were filtered to remove reads containing adapters or
reads of low quality, so that downstream analyses were based on clean reads. The
filtering process was as follows: (1) discard reads with adaptor contamination, (2)
discard reads when uncertain nucleotides constitute more than 10% of either read
(N > 10%), (3) discard reads when low quality nucleotides (base quality <20)
constitute >50% of the read.
RNA-seq Adapter sequences (Oligonucleotide sequences of adapters from
TruSeqTM RNA and DNA Sample Prep Kits):
RNA 5ʹ Adapter (RA5), part # 15013205:
5ʹ-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCT-3ʹ
RNA 3ʹ Adapter (RA3), part # 15013207: 5ʹ-GATCGGAAGAGCACACGTCT
GAACTCCAGTCAC (6-nucleotide index) ATCTCGTATGCCGTCTTCTGCTT
G-3ʹ
Mapping to a reference genome: Algorithm for mapping sequences: appropriate
software was chosen according to the characteristics of the reference genome.
TopHat2 was run for tumor genomes. The mismatch parameter were set to two,
and other parameters were set to default. Only filtered reads are used to analyze the
mapping status of RNA-seq data to the reference genome.
Expression quantification: Gene expression level was measured by transcript
abundance to generate FPKM counts, short for the expected number of Fragments
Per Kilobase of transcript sequence per Millions base pairs sequenced, which takes
into account the effects of both sequencing depth and gene length counting of
fragments. HTSeq software was used to analyze the gene expression levels in this
experiment, using the union mode. The result files present the number of genes
with different expression levels and the expression level of single genes. In general,
an FPKM value of 0.1 or 1 is set as the threshold for determining whether the gene
is expressed or not. Fragments Per Kilobase of transcript per Million mapped reads
(fkpm) values were ranked by the log2-transformed foldchange for knockout versus
wild-type.
FDG-PET imaging and analysis. Small-animal PET/CT scans were performed
using microPET/CT system Genisys 8 (Sofie Bioscience). Mice were fasted for 4 h,
placed on a heating pad to warm the mice for 60 min, and then anesthetized using
1.5–2% isoflurane. 20 μCi of 18F-FDG probes was administrated via tail vein.
Acquisition of static PET images was started 60 min after probe injection.
Maximum-likelihood expectation maximization with 60 iterations was used for
PET image reconstruction. All images were corrected for photon attenuation. The
CT acquisition parameters were 40 kVp, 190 mA, and 720 projections with an
exposure time of 55 ms at each projection. 86Y-AABD PET imaging was acquired
14 h after injection. For image analysis, PET/CT images were analyzed using OsiriX
Imaging Software (Version 3.9.3; Pixmeo SARL, Bernex, Switzerland).
Statistics and reproducibility. Experiments were performed on male and female
animals in approximately equal numbers with no apparent difference in phenotype
between sexes. All phenotypes described are representative of a minimum of n= 3
littermate pairs (or a total of six mice) as indicated in the description of each
experiment. For analysis of the hair regrowth phenotype, no statistical measure was
used to determine the sample size beforehand, nor were statistics used to measure
effects, as the results were essentially positive or negative as represented in the
figures. The results described include data from all treated animals. Investigators
were not blinded to allocation during the experimental data collection. Experi-
ments were not randomized. All results shown are representative images from at
least three independently treated animals, and genotyping was performed both
before and after animal treatment for confirmation. Pairwise comparisons between
two groups were performed by two-tailed statistical analysis using Student’s t test.
Statistical significances were considered if *p < 0.05; **p < 0.01; ***p < 0.001.
Experimental data are demonstrated as the mean ± SEM. Sample size and statistical
details can be found in the figure legends.
Data availability
Previously published transcriptomics data that were reanalyzed here are available
under accession (NIH GEO GSE111997). Normalized metabolite data are avail-
able at figshare.com: Figure 1 c, d; Fig. 3 d–f; Supplementary Figure 4 (Exp 5),
https://doi.org/10.6084/m9.figshare.7194761 [https://figshare.com/s/
4d9b59a0e4fd85dc9c9b]. Figure 1 c, d; Fig. 3d–f; Supplementary Figure 4 (Exp 4),
https://doi.org/10.6084/m9.figshare.7194809 [https://figshare.com/s/
df136b2a3154195e7315]. Figure 1c, d; Fig. 3d–f; Supplementary Figure 4 (Exp 3),
https://doi.org/10.6084/m9.figshare.7194833 [https://figshare.com/s/
86b1503620e50cdd5fe9]. Figure 1 c, d; Fig. 3d–f; Supplementary Figure 4 (Exp 2),
https://doi.org/10.6084/m9.figshare.7194836 [https://figshare.com/s/
f33a0d482412cef627e3]. Figure 1 c, d; Fig. 3d–f; Supplementary Figure 4 (Exp 1),
https://doi.org/10.6084/m9.figshare.7194839 [https://figshare.com/s/
34f29012ddec6e457e1b]. Supplementary Figure 5, https://doi.org/10.6084/m9.
figshare.7194851 [https://figshare.com/s/c2f7dd6edfededce0239]. Figure 7a, d–f
https://doi.org/10.6084/m9.figshare.7194857 [https://figshare.com/s/
48038002f6d30ed28b28]. Figure 6g (Exp 2) https://doi.org/10.6084/m9.
figshare.7194860 [https://figshare.com/s/2a245272e321f993d360]. Figure 6g (Exp
1) https://doi.org/10.6084/m9.figshare.7194869 [https://figshare.com/s/
297a51614d6eecd09443]. All other data supporting the findings of this study are
available from the corresponding author on reasonable request.
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